Project Grant R01CA279401
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$661K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $816,554 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to The University of Texas MD Anderson Cancer Center to develop and validate a mouse model of chemotherapy-induced peripheral neuropathy (CIPN) associated with colorectal cancer. The project aims to replicate the impact of tumor growth, surgical resection, and oxaliplatin-based chemotherapy on the development of sustained pain...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $181,448 to Virginia Commonwealth University (VCU) to investigate the use of the NLRP3 inflammasome inhibitor dapansutrile to treat chemotherapy-induced peripheral neuropathy (CIPN) in animal models. The key objectives are to determine if dapansutrile can alleviate and prevent CIPN symptoms induced by paclitaxel and cisplatin chemotherapies, both in naive mice and in...
This $419,474 project grant from the National Cancer Institute, part of the Department of Health and Human Services, supports research under the Cancer Treatment Research program to develop mechanism-based strategies to treat chemotherapy-induced peripheral neuropathy. The awardee, Washington University, will utilize a SARM1 dominant-negative construct and virus-mediated overexpression of NAD+ salvage pathway enzymes to block the axon degeneration pathway activated by chemotherapeutic agents...
This Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research to identify molecular and cellular mechanisms underlying paclitaxel-induced peripheral neuropathy (PIPN), a common adverse effect of the chemotherapy drug paclitaxel. The $402,874 award to the University of Texas Medical Branch at Galveston aims to investigate the role of acute excitation of sensory neurons in the development of PIPN. Key objectives include:...
This Project Grant award, totaling $5,666,172, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279). The objective is to study the role of Schwann cell signaling pathways, specifically the PPAR-gamma and LRP1 pathways, in regulating neuronal mitochondrial function and excitability in the context of chemotherapy-induced painful peripheral neuropathy (CIPPN). The research approach involves in vitro...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $179,403.00 to support research into developing flupirtine analogue compounds that can effectively treat chemotherapy-induced neuropathic pain (CINP) while avoiding the liver toxicity issues associated with the parent flupirtine compound. The award aims to: (1) strategically develop potent Kv7.2/7.3 activators that do not form hepatotoxic metabolites, and (2) determine the...
This $589,106 Project Grant was awarded by the National Institute on Aging (NIA) under the Aging Research Federal Grant Program (CFDA 93.866) to The Washington University in St. Louis. The grant, awarded on June 1, 2025, with an ultimate completion date of March 31, 2030, will support research to elucidate how senescent stromal cells drive chemotherapy-induced peripheral neuropathy (CIPN). The project aims to 1) determine the impact of senescence on axonal loss in CIPN, and 2) identify senescent...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) for $1,239,420 will fund a longitudinal observational study to assess changes in interoception (the brain's processing of sensations from the body) among 120 patients with breast or gastrointestinal cancer receiving taxane or platinum chemotherapy, compared to 60 healthy controls. The study aims to understand how interoception changes across the cancer chemotherapy continuum...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $391,325.00 to the University of Arizona to develop a new portable confocal microscope for rapidly imaging Meissner's corpuscles (MCs), which are important biomarkers for assessing chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients. The award period runs from February 21, 2025 to January 31, 2030. The key products to be delivered are: 1) a new portable confocal...
The National Cancer Institute (NCI) awarded a $386,781 Project Grant under the Cancer Treatment Research (CFDA 93.395) program to Hobart & William Smith Colleges to conduct multidisciplinary research on developing novel heterocyclic tubulin polymerization inhibitors as potential cancer treatments. The project aims to characterize previously identified tubulin-binding compounds, employ rational drug design to identify new heterocyclic tubulin inhibitors, and apply innovative synthetic methods...